Other equities research analysts have also issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $22.50 price target on shares of Codexis in a research report on Thursday, August 8th. Zacks Investment Research lowered Codexis from a hold rating to a sell rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Codexis presently has a consensus rating of Buy and a consensus price target of $21.58.
NASDAQ:CDXS opened at $13.39 on Thursday. Codexis has a 1-year low of $12.81 and a 1-year high of $23.05. The business’s 50-day moving average price is $17.57 and its two-hundred day moving average price is $19.31. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.30 and a quick ratio of 6.26.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Investment Advisory Services LLC acquired a new stake in shares of Codexis during the second quarter worth about $37,000. Tower Research Capital LLC TRC acquired a new stake in shares of Codexis during the second quarter worth about $41,000. Quantamental Technologies LLC acquired a new stake in shares of Codexis during the second quarter worth about $44,000. Aperio Group LLC acquired a new stake in shares of Codexis during the second quarter worth about $98,000. Finally, Legal & General Group Plc raised its position in shares of Codexis by 12.1% during the fourth quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 1,010 shares during the period. 87.27% of the stock is currently owned by institutional investors.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Article: Call Option Volume
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.